Proventys is developing a suite of validated predictive tests (PDx) that help physicians individualize treatment decisions for patients at the point of care. The company’s lead PDx, delivered through the Proventys PDx Oncology™ system, is a predictive test to assess an adult cancer patient’s risk of developing chemotherapy-induced febrile neutropenia (FN), an adverse event marked by high fever, serious infection and hospitalization.

Results of the FN PDx are used by the physician to help determine if appropriate therapy should be prescribed as a preventive measure to a given patient, as suggested by published guidelines.

Proventys PDx Oncology™ is pending 510(k), not available for sale in the United States.